Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Completed No phase listed Observational

Study of Pediatric Migraine: The Pediatric Migraine Registry

NCT03742024
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
4 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
San Francisco, California • Colorado Springs, Colorado • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00039962
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of AV-001 in Healthy Subjects

NCT04737486
View directory record Official record
Conditions
Covid19-associated ARDS, Covid19, ARDS
Interventions
AV-001, Placebo
Drug · Other
Lead sponsor
Vasomune Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

NCT01429441
View directory record Official record
Conditions
Vitreomacular Adhesion Including Macular Hole
Interventions
Ocriplasmin, Sham injection
Drug · Other
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 31, 2026, 9:56 AM EDT
Terminated Phase 4 Interventional Results available

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

NCT01856023
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
High Dose Interleukin-2, Ipilimumab
Drug
Lead sponsor
Clinigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 31, 2026, 9:56 AM EDT
Terminated Phase 3 Interventional

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence

NCT00895479
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Graft placement surgery plus Trinam therapy
Procedure
Lead sponsor
Ark Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Long Beach, California • Paducah, Kentucky • Baton Rouge, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study

NCT02542462
View directory record Official record
Conditions
Intussusception, Rotavirus Infections
Interventions
Rotarix®,, Rotarix®, with other routine vaccines, RotaTeq®,, RotaTeq®, with other routine vaccines
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
42 Days to 90 Days
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Lesinurad Monotherapy Extension Study in Gout

NCT01650246
View directory record Official record
Conditions
Gout
Interventions
lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

NCT00686920
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Aurora, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 31, 2026, 9:56 AM EDT
Completed No phase listed Observational

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

NCT00003096
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
DNA ploidy analysis, comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • Downey, California • Loma Linda, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 31, 2026, 9:56 AM EDT
Not listed No phase listed Observational

Prospective SPINE Registry

NCT04176562
View directory record Official record
Conditions
Sacroiliac; Fusion, Sacroiliac, Joint Diseases, Musculoskeletal Diseases, Spinal Disease, Spinal Stenosis, Spinal Instability, Fusion of Joint, Fusion of Spine, Spinal Fusion, Spine
Interventions
RTI Spine products
Device
Lead sponsor
Xtant Medical
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Hartford, Connecticut • Boca Raton, Florida • Delray Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine Versus Interscalene Nerve Block

NCT03929146
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Exparel, Interscalene Nerve Block
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 4 Interventional Results available

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study

NCT03687827
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 2 Interventional Results available

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

NCT03940586
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infection
Interventions
Letermovir oral granules, Letermovir tablet, Letermovir intravenous
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Duarte, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

NCT05028361
View directory record Official record
Conditions
Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions
mRNA COVID-19, IIV4, Placebo (saline)
Biological · Other
Lead sponsor
Duke University
Other
Eligibility
5 Years and older
Enrollment
348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes

NCT01034527
View directory record Official record
Conditions
ACL Injury
Interventions
Neuromuscular Training
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 19 Years · Female only
Enrollment
593 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 31, 2026, 9:56 AM EDT
Not listed Not applicable Interventional

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

NCT00238342
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer
Interventions
proteomic profiling, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy
Genetic · Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
107
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Burbank, California + 80 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Oct 31, 2026, 9:56 AM EDT
Not listed Not applicable Interventional

RejuvenAir® System Trial for COPD With Chronic Bronchitis

NCT03893370
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
RejuvenAir System, Sham Control Procedure
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Mountain View, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 31, 2026, 9:56 AM EDT
Not listed Phase 3 Interventional

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

NCT02615873
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years to 100 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

NCT02959983
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
76
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 31, 2026, 9:56 AM EDT
Not listed Phase 3 Interventional

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

NCT02652429
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 31, 2026, 9:56 AM EDT
Completed Not applicable Interventional

Acupuncture for Sexual Dysfunction

NCT02070029
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD), Low Libido, Female Sexual Dysfunction (FSD)
Interventions
Acupuncture
Procedure
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 31, 2026, 9:56 AM EDT
Suspended Phase 1 Interventional

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

NCT04746131
View directory record Official record
Conditions
B-cell Non-Hodgkin's Lymphoma
Interventions
IMM0306
Drug
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 31, 2026, 9:56 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

NCT02737202
View directory record Official record
Conditions
Pulmonary Lymphangioleiomyomatosis
Interventions
saracatinib
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Stanford, California • Chicago, Illinois • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 31, 2026, 9:56 AM EDT